IVISbrite™ Salmonella typhimurium Xen33 bioluminescent bacteria was derived from the parental strain FDA 1189. For in vitro or in vivo imaging applications, IVISbrite S. typhimurium-Xen33 possesses a stable copy of the Photorhabdus luminescens lux operon on the bacterial chromosome.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Infectious disease is a perennially important area for both life science research and drug discovery. Some of the first applications of IVIS® imaging technology were in tracking infections and monitoring host responses, and these applications are still at the forefront of research. Our bioluminescent infectious disease light-producing microorganisms have been developed to mimic both acute and chronic standard infection protocols presently used by researchers.
Advantages of using bioluminescent light-producing microorganisms for drug discovery in vitro:
Advantages of using bioluminescent light-producing microorganisms for drug discovery in vivo:
|Gram Positive Gram Negative||Gram negative|
|Luciferase Classification||Bacterial luciferase|
|Optical Imaging Classification||Bioluminescence Imaging|
|Product Brand Name||IVISbrite|
|Therapeutic Area||Infectious Diseases|
|Unit Size||1 agar plate|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.